BeOne Medicines (BEIGF) Operating Leases (2019 - 2025)
Historic Operating Leases for BeOne Medicines (BEIGF) over the last 7 years, with Q3 2025 value amounting to $51.4 million.
- BeOne Medicines' Operating Leases rose 5833.8% to $51.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year increase of 5833.8%. This contributed to the annual value of $44.3 million for FY2024, which is 17.19% up from last year.
- Per BeOne Medicines' latest filing, its Operating Leases stood at $51.4 million for Q3 2025, which was up 5833.8% from $53.9 million recorded in Q2 2025.
- Over the past 5 years, BeOne Medicines' Operating Leases peaked at $65.0 million during Q4 2021, and registered a low of $17.7 million during Q1 2024.
- For the 5-year period, BeOne Medicines' Operating Leases averaged around $39.9 million, with its median value being $37.6 million (2021).
- In the last 5 years, BeOne Medicines' Operating Leases crashed by 4554.28% in 2024 and then surged by 20975.62% in 2025.
- BeOne Medicines' Operating Leases (Quarter) stood at $65.0 million in 2021, then fell by 9.86% to $58.6 million in 2022, then decreased by 24.52% to $44.2 million in 2023, then rose by 0.17% to $44.3 million in 2024, then grew by 16.06% to $51.4 million in 2025.
- Its Operating Leases stands at $51.4 million for Q3 2025, versus $53.9 million for Q2 2025 and $54.9 million for Q1 2025.